Influence of CYP2D6 and CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy volunteers

被引:0
作者
M. Pawlowska
M. Bogiel
J. Duda
E. Sieradzki
机构
[1] Institute of Biotechnology and Antibiotics,Faculty of Pharmacy, Department of Applied Pharmacy and Bioengineering
[2] Medical University of Warsaw,undefined
来源
European Journal of Clinical Pharmacology | 2015年 / 71卷
关键词
Tolperisone; Polymorphism; Pharmacokinetics;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:699 / 705
页数:6
相关论文
共 105 条
[1]  
Nagata K(2002)Genetic polymorphism on human cytochrome P450 involved in drug metabolism Drug Metabol Pharmacokinet 17 167-189
[2]  
Yamazoe Y(2013)Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation Pharmacol Ther 138 103-141
[3]  
Zanger UM(2013)Drug metabolites as cytochrome p450 inhibitors: a retrospective analysis and proposed algorithm for evaluation of the pharmacokinetic interaction potential of metabolites in drug discovery and development Drug Metab Dispos 41 2047-2055
[4]  
Schwab M(2012)Genetic polymorphisms affecting drug metabolism: recent advances and clinical aspects Adv Pharmacol 63 137-167
[5]  
Callegari E(2012)Where are we today with personalized medicine? J Psychosoc Nurs Ment Health Serv 50 11-13
[6]  
Kalgutkar AS(2003)Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes Drug Metab Dispos 31 631-636
[7]  
Leung L(2000)Synthesis and resolution of a tolperisone metabolite Tetrahedron-Asymmetry 11 1323-1329
[8]  
Obach RS(2001)Synthesis, resolution and absolute configuration of a tolperisone metabolite Tetrahedron-Asymmetry 12 719-724
[9]  
Plowchalk DR(2002)Synthesis of some tolperisone metabolites in racemic and optically active form Tetrahedron-Asymmetry 12 3417-3422
[10]  
Tse S(2003)Pharmacogenetics of the major polymorphic metabolizing enzymes Fundam Clin Pharmacol 17 27-41